Mark Talamonti to Antimetabolites, Antineoplastic
This is a "connection" page, showing publications Mark Talamonti has written about Antimetabolites, Antineoplastic.
Connection Strength
0.499
-
A multi-institutional phase II trial of preoperative full-dose gemcitabine and concurrent radiation for patients with potentially resectable pancreatic carcinoma. Ann Surg Oncol. 2006 Feb; 13(2):150-8.
Score: 0.237
-
Time to Initiation of Adjuvant Chemotherapy in Pancreas Cancer: A Multi-Institutional Experience. Ann Surg Oncol. 2017 Sep; 24(9):2770-2776.
Score: 0.131
-
Full-dose gemcitabine with concurrent radiation therapy in patients with nonmetastatic pancreatic cancer: a multicenter phase II trial. J Clin Oncol. 2008 Feb 20; 26(6):942-7.
Score: 0.069
-
The vitamin D receptor gene as a determinant of survival in pancreatic cancer patients: Genomic analysis and experimental validation. PLoS One. 2018; 13(8):e0202272.
Score: 0.035
-
Pancreatic adenocarcinoma. Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2007 Nov; 5(10):998-1033.
Score: 0.017
-
Molecular markers and prediction of response to chemoradiation in rectal cancer. Oncol Rep. 2001 May-Jun; 8(3):497-500.
Score: 0.011